Home > Boards > US Listed > Biotechs > Heron Therapeutics Inc. (HRTX)

https://ih.advfn.com/p.php?pid=nmona&article=77714461"Item 7.01 Regulation FD Disclosur

Public Reply | Private Reply | Keep | Last ReadPost New MsgPrevious | Next
north40000 Member Profile
Member Level 
Followed By 167
Posts 14,928
Boards Moderated 0
Alias Born 01/19/06
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/23/2019 8:40:33 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/21/2019 9:16:32 AM
Heron Therapeutics Announces Publication of Results from Phase 3 EPOCH 1 Study of HTX-011 in Patients Undergoing Bunionectomy PR Newswire (US) - 5/21/2019 9:13:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/16/2019 8:45:48 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/14/2019 8:36:20 AM
Heron Therapeutics Presents New Results from Real-world Study Showing 95% of Postoperative Patients Remain Opioid-Free when H... PR Newswire (US) - 5/14/2019 8:30:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/9/2019 8:45:52 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/9/2019 8:40:44 AM
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2019 and Highlights Recent Corporate Prog... PR Newswire (US) - 5/9/2019 8:30:00 AM
Heron Therapeutics to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference PR Newswire (US) - 5/8/2019 4:05:00 PM
Heron Therapeutics Partners with the National Academy of Medicine to Counter the Opioid Epidemic in the United States PR Newswire (US) - 5/7/2019 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/1/2019 8:08:05 AM
Heron Therapeutics Receives Complete Response Letter For HTX-011 For The Management Of Postoperative Pain PR Newswire (US) - 5/1/2019 8:00:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/26/2019 4:58:18 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/26/2019 4:54:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/1/2019 8:37:13 AM
Heron Announces European Medicines Agency Validation of Marketing Authorisation Application for HTX-011 for Postoperative Pai... PR Newswire (US) - 4/1/2019 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/11/2019 8:40:24 AM
77% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Posto... PR Newswire (US) - 3/11/2019 8:30:00 AM
Heron Therapeutics to Present at the 39th Annual Cowen Healthcare Conference PR Newswire (US) - 3/4/2019 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/26/2019 4:13:24 PM
Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI® Label for IV Push PR Newswire (US) - 2/26/2019 4:05:00 PM
Annual Report (10-k) Edgar (US Regulatory) - 2/22/2019 8:50:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/22/2019 8:42:05 AM
Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2018 and Recent Corporate P... PR Newswire (US) - 2/22/2019 8:30:00 AM
north40000 Member Level  Thursday, 06/21/18 03:27:32 PM
Re: None
Post # of 5890 
https://ih.advfn.com/p.php?pid=nmona&article=77714461

"Item 7.01 Regulation FD Disclosure.
On June 21, 2018, Heron Therapeutics, Inc. (the “Company”) issued a press release announcing positive topline results from its Phase 2b study of HTX-011 in subjects undergoing total knee arthroplasty and breast augmentation, as described in the press release furnished herewith as Exhibit 99.1.

The Company also issued a press release announcing that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to the Company’s investigational agent, HTX-011, for postoperative pain management, as described in the press release furnished herewith as Exhibit 99.2.

A copy of presentation materials describing a Company update, all or a part of which may be used by the Company in investor or scientific presentations from time to time, is furnished as Exhibit 99.3 hereto. The attached materials have also been posted on the Company’s website at www.herontx.com . The Company does not undertake any obligation to update this presentation.



Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.



Exhibit
No. Description
99.1 Press Release, dated June 21, 2018
99.2 Press Release, dated June 21, 2018
99.3 Corporate Presentation, dated June 21, 2018"

**********************************

"About HTX-011 for Postoperative Pain

HTX-011, which utilizes Heron’s proprietary Biochronomer® drug delivery technology, is an investigational, long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the management of postoperative pain. By delivering sustained levels of both a potent anesthetic and a local anti-inflammatory agent directly to the site of tissue injury, HTX-011 was designed to deliver superior pain relief while reducing the need for systemically administered pain medications such as opioids, which carry the risk of harmful side effects, abuse and addiction. HTX-011 has been shown to reduce pain significantly better than placebo or bupivacaine alone in five diverse surgical models: hernia repair, abdominoplasty, bunionectomy, total knee arthroplasty and breast augmentation. HTX-011 was granted Fast Track designation from the FDA in the fourth quarter of 2017 and Breakthrough Therapy designation in the second quarter of 2018. In the second half of 2018, Heron expects to submit a New Drug Application (NDA) to the FDA for HTX-011."

Public Reply | Private Reply | Keep | Last ReadPost New MsgPrevious | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist